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International guidelines define a BK virus (BKV) load of>4 log10 copies/ml as presumptive of BKV-associated nephropathy
(BKVN) and a cutoff for therapeutic intervention. To investigate whether BKVDNA loads (BKVL) are comparable between lab-
oratories, 2 panels of 15 and 8 clinical specimens (urine, whole blood, and plasma) harboring different BKV genotypes were dis-
tributed to 20 and 27 French hospital centers in 2013 and 2014, respectively. Although 68% of the reported results fell within the
acceptable range of the expected result0.5 log10, the interlaboratory variation ranged from 1.32 to 5.55 log10. Polymorphisms
specific to BKV genotypes II and IV, namely, the number and position of mutations in amplification target genes and/or deletion
in standards, arose as major sources of interlaboratory disagreements. The diversity of DNA purificationmethods also contrib-
uted to the interlaboratory variability, in particular for urine samples. Our data strongly suggest that (i) commercial external
quality controls for BKVL assessment should include all major BKV genotypes to allow a correct evaluation of BKV assays, and
(ii) the BKV sequence of commercial standards should be provided to users to verify the absence of mismatches with the primers
and probes of their BKV assays. Finally, the optimization of primer and probe design and standardization of DNA extraction
methods may substantially decrease interlaboratory variability and allow interinstitutional studies to define a universal cutoff
for presumptive BKVN and, ultimately, ensure adequate patient care.
The emergence of BK virus-associated nephropathy (BKVN) asa major cause of graft dysfunction and loss in kidney trans-
plant recipients (KTR) arises from the use of highly potent immu-
nosuppressive drugs (1–3). This is a growing medical problem as
the population of transplant recipients continues to increase. In
Europe and the United States, the number of kidney transplanta-
tions has increased up to 50% in the last 20 years (www.kidney
.niddk.nih.gov and http://www.era-edta.org). BKV reactivation
or reinfection occurs in 40 to 50% of KTR, followed by BKVN in
6.6% of KTR at 5 years posttransplant, ultimately leading to graft
dysfunction and loss in up to 50% of cases (4). The diagnosis of
BKVN is based on the documentation of viral cytopathic effects
observed in tubular epithelial cells accompanied by inflammatory
cell infiltration after renal biopsy (5, 6). Immunohistochemistry
with SV40 staining is the gold standard for diagnosing definitive
BKVN (7). Nevertheless, in the early stages of BKVN, kidney allo-
graft biopsy results may be falsely negative at an estimated rate of
10 to 30% (8). Prospective studies showed that high BKV viruria
usually precedes viremia by 4 to 12 weeks, with a sustained BKV
viremia above the threshold of 4 log10 copies/ml defined as pre-
sumptive of BKVN, with a positive predictive value of 80% (9,
10). These studies showed that BKVN can be effectively and safely
prevented using a preemptive reduction in immunosuppression
(11, 12). Therefore, European and Kidney Disease Improving
Global Outcomes (KDIGO) guidelines recommend monthly KTR
screening for BKV replication in urine and plasma specimens in
the first 6 months posttransplant and then every 3 months until 2
years posttransplant (13, 14) to guide therapeutic intervention for
KTR with presumptive BKVN.
Monitoring of BKV replication has been improved by the de-
velopment of real-time quantitative PCR (qPCR) assays showing
high sensitivity and specificity (15). However, the wide variety of
available qPCR assays and the lack of international standards limit
interlaboratory comparison (16, 17).
The distribution of proficiency panels constitutes a relevant
approach to assess the variability of BK virus DNA load (BKVL)
and to compare interlaboratory results, as shown for other oppor-
tunistic viruses, such as cytomegalovirus (CMV) and Epstein-Barr
virus (EBV) (18, 19). High interlaboratory variability prompted
international collaboration groups to establish WHO reference
standards for these viruses (20, 21).
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In this study, we assessed BKVL variability in several French
hospital centers that conduct nearly 90% of the kidney transplan-
tation activity in France. Two panels of clinical samples, including
BKV genotype II and IV for the first time, were distributed to
compare the performances of individual laboratories and analyze
factors that may influence interlaboratory comparison (22).
MATERIALS AND METHODS
Panel constitution and preparation. The 2013 panel consisted of 15 clin-
ical samples, including 5 urine (BKV13-01 to BKV13-05), 5 whole blood
(WB) (BKV13-06 to BKV13-10), and 5 plasma (BKV13-11 to BKV13-15)
specimens. Positive samples were collected from 20 patients, including 14
kidney, 4 lung, and 2 hematopoietic stem cell transplant recipients. The
2014 panel included 4 urine (BKV14-01, BKV14-03 [a replicate of
BKV14-01], BKV14-02, and BKV14-04), 2 WB (BKV14-05 and BKV14-
06), and 2 plasma (BKV14-07 and BKV14-08) specimens. Positive sam-
ples in the 2014 panel were collected from 4 kidney transplant recipients
and 1 hematopoietic stem cell transplant patient. Clinical samples of the
same matrix and with equivalent DNA viral loads were pooled to prepare
adequate volumes of panel samples. The samples were homogenized be-
fore and after pooling by gentle mixing using a tube rotator for 20 min.
Samples with mixed genotypes were obtained by mixing 2 to 3 single-
genotype samples. As shown in Table 1, 11 BKV-positive samples harbor-
ing a single BKV genotype and 8 samples harboring multiple BKV geno-
types were chosen to represent a wide range of BKV DNA concentrations.
The negative samples (BKV13-08, BKV13-11, BKV14-06, and BKV14-07)
were prepared from plasma and WB specimens collected from KTR who
tested negative for BKV DNA3 months before and 3 months after the
collection date.
The panel samples were aliquoted, coded, and frozen at 80°C until
shipment to the participating laboratories. Aliquots from the same panel
were prepared the same day by a single technician using 1 calibrated pi-
pette to minimize any variation and possible errors in preparations. Urine
and blood samples were collected at the Strasbourg University Hospital
(Strasbourg, France) and previously tested for BKV by our routine diag-
nostic testing with the CE-marked BK virus R-gene kit (bioMérieux,
Marcy l’Etoile, France). The performance of our routine test is evaluated
annually by the Quality Control for Molecular Diagnostics (QCMD) (23).
This study was approved by the institutional review board of Strasbourg
University Hospital.
Study participants. Twenty and 27 French hospital laboratories per-
forming diagnostic testing of BKVL were invited and agreed to participate
in this study in 2013 and 2014, respectively. Each participant completed a
questionnaire detailing the procedure employed for BKV testing. Panel
samples were shipped by a laboratory-specialized courier. The partici-
pants were asked to test the samples as if they were routine diagnostic
specimens and to return the results within 10 weeks.
BKV genome sequencing. Amplification of the small T-antigen gene
(StAg) and the BKV capsid viral protein 1 gene (VP1) was performed, as
previously described (23). The large T-antigen gene (LTAg) was sequenced
using primers BK6F (5=-GCCATTCCTTGCAGTACAGG-3= [positions 4859
to 4878]) and BK6R (5=-GAGCTCATGGACCTTTTAGGC-3= [positions
5120 to 5100]). BKV genotyping was performed as previously described (24).
Results analysis and statistics. For qualitative analysis of the data
sets, results reported as negative, undetectable, or below the limit of
detection were considered negative, while positive values reported
with an absolute quantification or above the limit of detection were
considered positive. False-positive and false-negative results and re-
TABLE 1 Quantitative results of the 2013 and 2014 BKV panelsa
Sample no.
by source
BKV
genotype(s)
Quantitative results (log10 copies/ml) for:
All data sets (maximum n 28)
Commercial assays (maximum
n 23) In-house assays (maximum n 5)
GM SD Spread (range) GM SD Spread (range) GM SD Spread (range)
Urine
BKV13-01 I 4.79 0.64 2.23 (3.92–6.15) 4.68 0.53 2.12 (4.03–6.15) 5.11 0.84 1.99 (3.92–5.91)
BKV13-02 I 6.14 0.45 1.89 (5.34–7.23) 5.97 0.28 1.05 (5.34–6.39) 6.65 0.49 1.12 (6.11–7.23)
BKV13-03 I, IV 6.98 0.71 3.20 (5.28–8.48) 6.80 0.65 2.20 (5.28–7.48) 7.52 0.63 1.62 (6.86–8.48)
BKV13-04 II, IV 8.81 0.67 2.60 (7.72–10.32) 8.80 0.41 1.23 (8.18–9.41) 8.85 1.18 2.60 (7.72–10.32)
BKV13-05 I 9.32 0.65 2.32 (8.12–10.44) 9.23 0.48 1.50 (8.45–9.95) 9.55 0.96 2.32 (8.12–10.44)
BKV14-01 IV 7.37 0.66 3.30 (5.32–8.62) 7.47 0.53 2.00 (6.62–8.62) 6.90 1.03 2.63 (5.32–7.95)
BKV14-02 I 9.85 0.47 2.10 (8.54–10.64) 9.87 0.49 2.10 (8.54–10.64) 9.75 0.39 0.97 (9.33–10.30)
BKV14-03 IV 7.28 0.64 2.98 (5.36–8.34) 7.37 0.54 2.06 (6.28–8.34) 6.89 0.99 2.63 (5.36–7.99)
BKV14-04 II 8.58 1.07 5.55 (4.58–10.13) 8.91 0.31 1.38 (8.12–9.50) 7.25 2.29 5.55 (4.58–10.13)
WBb
BKV13-06 I, II, IV 3.69 0.84 3.43 (1.85–5.28) 3.52 0.78 3.18 (1.85–5.03) 4.30 0.89 2.00 (3.28–5.28)
BKV13-07 I, IV 4.91 0.50 1.98 (4.21–6.19) 4.75 0.35 1.10 (4.21–5.31) 5.39 0.57 1.61 (4.58–6.19)
BKV13-09 I, II 4.96 0.61 4.91 (3.72–6.61) 4.74 0.44 1.72 (3.72–5.44) 5.63 0.57 1.39 (5.22–6.61)
BKV13-10 I, IV 3.72 0.72 2.67 (2.51–5.18) 3.54 0.65 2.44 (2.51–4.95) 4.24 0.71 1.84 (3.34–5.18)
BKV14-05 I 3.99 0.52 2.60 (2.23–4.83) 3.88 0.52 2.60 (2.23–4.83) 4.50 0.14 0.36 (4.25–4.61)
Plasma
BKV13-12 I 4.99 0.63 2.81 (4.35–7.16) 4.75 0.26 1.03 (4.35–5.38) 5.71 0.83 2.03 (5.13–7.16)
BKV13-13 I 4.26 0.48 1.88 (3.52–5.40) 4.07 0.32 1.32 (3.52–4.84) 4.85 0.38 1.03 (4.37–5.40)
BKV13-14 I, IV 6.34 0.45 1.73 (5.79–7.52) 6.14 0.24 0.97 (5.79–6.76) 6.93 0.39 0.95 (6.57–7.52)
BKV13-15 I, IV 6.07 0.52 2.12 (5.23–7.35) 5.91 0.41 1.67 (5.23–6.90) 6.55 0.55 1.47 (5.88–7.35)
BKV14-08 I 6.27 0.33 1.32 (5.47–6.79) 6.20 0.31 1.30 (5.47–6.77) 6.61 0.17 0.37 (6.42–6.79)
a Geometric mean (GM), SD, and spread were calculated with quantitative positive results reported from all participants. Results reported as negative or under or over the limit of
quantification were excluded. BKV genotypes constituting each panel sample are reported.
b WB, whole blood.
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sults reported outside the limits of quantification were excluded from
the quantitative analysis.
For each sample, the expected viral load to which all results were com-
pared was defined as the geometric mean of the positive quantitative re-
sults reported by all participating laboratories. Variability according to
viral load, matrix, and genotype was compared based on the standard
deviations within each group, as previously described (25). Nonparamet-
ric tests (Mann-Whitney and Kruskal-Wallis tests) were used, and pair-
wise multiple comparisons between groups were analyzed using Dunn’s
multiple-comparison test. All statistical analyses were performed using
the GraphPad Prism 6 software (San Diego, CA, USA).
RESULTS
Characteristics of participating laboratories andutilized assays.
Twenty-seven French hospital laboratories were sent the 2014
8-sample study panel, including the 20 laboratories that partici-
pated in the 2013 15-sample study. Two laboratories performing
different assays were sent1 panel. Nineteen (95%) and 25 (93%)
laboratories returned results in 2013 and 2014, respectively. A
total of 47 data sets were used for the final analysis, including 19
from 19 laboratories in 2013 and 28 from 25 laboratories in 2014.
Marked variability was observed in terms of techniques, target
genes, matrix used for the blood compartment, and DNA extrac-
tion methods (Fig. 1). Most laboratories (81%) used commercial
assays (Fig. 1A), including the BK virus R-gene kit (n 15) (bio-
Mérieux, Marcy l’Etoile, France), the RealStar BKV PCR kit (n
3) (Altona Diagnostics/Eurobio, Courtaboeuf, France), the Light-
Mix polyomaviruses JC and BK kit (n  2) (TibMolBiol, Berlin,
FIG 1 Diversity of diagnostic conditions among the participants. Participating laboratories were asked to describe the type (A) and target (B) of the qPCR assay
routinely used for BK viral load quantification, the matrix routinely tested in the blood compartment (C), and the extraction methods used for DNA purification
(D). For laboratories using different extraction methods for urine and blood samples, both techniques were considered in our analysis. The percentages of
participants are indicated for each pie chart.
Solis et al.
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Germany), the artus BK virus RG PCR kit (n 2) (Qiagen GmbH,
Hilden, Germany), and the BKV ELITe MGB kit (n  1)
(ELITechGroup Molecular Diagnostics, Puteaux, France). Four
in-house assays, including 2 previously published in the literature
(26, 27) and one adapted from Hoffman et al. (17) were used by 5
(19%) laboratories. The unpublished assay (S. Rogez, S. Hantz,
and S. Alain) targeted the VP1 gene using the primer set forward
(5=-TTTGGGACTTTCACAGGAGG-3=) (positions 2227 to 2246,
Dunlop sequence]) and reverse (5=-GCCTCTCCACTGTTGTGT
TCC-3= [positions 2409 to 2389, Dunlop sequence]), and the
probe (5=-TGTTTCAGCTGCTGATATTTGTGGCC-3= [posi-
tions 2346 to 2371, Dunlop sequence]). Most of the assays tar-
geted the StAg or LTAg gene (Fig. 1B). The 5 laboratories perform-
ing in-house assays used different standard materials: BKV strain
MM quantitated DNA control (Advanced Biotechnologies, tebu-
bio, Le Perray-en-Yvelines, France) (ABI control) (n 2), which
is a whole BKV genome linearized at the BamHI site in the StAg
gene; the AmpliRun BK virus DNA control (Vircell S.L, Granada,
Spain) (Vircell control) (n  2), which is also a whole viral ge-
nome; or serial dilutions of qPCR amplification product cloned
into a vector (n  1). Each commercial kit contained its own
standard material, the composition of which is proprietary.
Amplicon sizes varied from 75 to 274 bp (see Table S1 in the
supplemental material). All participating laboratories routinely
performed BKVL assays with urine samples, whereas 62% of the
laboratories used WB samples, and 38% used plasma samples for
viral load determination in the peripheral blood compartment
(Fig. 1C). Nine different automated DNA extraction platforms,
89% of which were based on a magnetic bead method, were used
(Fig. 1D). Seventy-seven percent of the laboratories used the same
extraction method for urine and peripheral blood matrices, while
the remaining 23% used different extraction platforms depending
on the matrix, hindering normalization of the results (see Table S2
in the supplemental material). Regarding the urine samples, most
laboratories used resuspended or vortexed material, and no pellet
concentrates were used.
Among the 25 participants that returned results, 22 (88%) par-
ticipate annually in the QCMD program, including those using
in-house assays.
High concordance of qualitative results.Data from both pan-
els were pooled for qualitative analysis; only 4 out of 509 reported
results were incorrect. All samples with an expected BKVL of4.0
log10 copies/ml were detected as positive by all participants. One
false-negative result was reported by 1 laboratory using an in-
house qPCR assay targeting the VP1 gene (positions 2227 to 2409)
for a sample with an expected BKVL of 3.69 0.84 log10 copies/
ml. Three laboratories reported false-positive results for BKV13-
08, BKV13-11, and BKV14-07, respectively; the 3 participants
used different commercial qPCR assays targeting StAg or LTAg.
Important variability of quantitative results. The quantita-
tive results are summarized in Table 1 and Fig. 2. The geometric
mean BKVL ranged from 3.69 to 9.85 log10 copies/ml. The differ-
ence between the highest and the lowest viral loads reported by all
participants varied from 1.32 to 5.55 log10, with a mean value of
2.61 log10. The BKVL standard deviation (SD) ranged from 0.45 to
1.07 log10 copies/ml. The greatest SD was observed for the BKV
genotype II sample.
Technical variability of0.5 log10 is considered acceptable (18,
28) and of low clinical relevance (29). Thus, we compared labora-
tory performance by calculating the percentage of results falling
within the acceptable variation of 0.5 log10 relative to the ex-
pected value. Sixty-eight percent of the reported results fell within
the acceptable range (Fig. 3). Interestingly, for a plasma sample
(BKV genotype I) approaching the cutoff for therapeutic inter-
vention (BKV13-13, with an expected value of 4.26 log10 copies/
ml), 74% of laboratories reported a BKVL of 4 log10 copies/ml
(range, 4.00 to 5.40 log10 copies/ml), while only 26% reported
BKVL of4 log10 copies/ml (range, 3.52 to 3.98 log10 copies/ml).
The variability of BKVL in the 3 matrices (urine, WB, and
plasma) was not statistically different (P  0.08, Kruskal-Wallis
test) (Fig. 4). Intralaboratory variability investigated by the sample
replicated in the 2014 panel (BKV14-01/03) was significantly
lower than the interlaboratory variability (SD, 0.10 versus 0.65;
P 0.02, Mann-Whitney test).
Number and position of BKV polymorphisms impact BKVL
quantification. Several factors, including commercialized prim-
ers and probes, DNA extraction methods, amplification target
genes, and standard materials, were previously associated with
changes in viral load measurement (17, 30).
In our study, commercial assays demonstrated less variabil-
ity and better performance according to the above-mentioned
criterion, with 76% of the results falling within the acceptable
range versus 44% for in-house assays (P  0.0001, Mann-
Whitney test). We further compared the results of the 2014
panel (which included 8 data sets of commercial assays other
than the R-gene kit). The expected values obtained by labora-
tories using other commercial assays were not statistically dif-
ferent from those of laboratories using the R-gene kit, suggest-
ing that the better performance of commercial assays was not
biased by the high representativeness of the R-gene kit in our
study (see Fig. S1 in the supplemental material). Interestingly,
in a comparison of the results reported by laboratories using
the same qPCR assay, we still observed differences up to 2 log10,
suggesting that pre-qPCR steps, i.e., DNA purification, may
influence interlaboratory variability.
Three DNA extraction instruments, NucliSENS easyMAG
(bioMérieux, Marcy l’Etoile, France) (37%), QIAsymphony SP
(Qiagen GmbH, Hilden, Germany) (19%), and MagNA Pure
LC 2.0 (Roche Diagnostics, France) (15%), were predomi-
nantly used by the participants. The results obtained from 12
and 15 users of the R-gene qPCR assay in 2013 and 2014, re-
spectively, were analyzed depending on the extraction method.
The performance of DNA extraction was significantly different
between the 3 platforms (P  0.001, Kruskal-Wallis test). The
MagNA Pure LC showed lower performance for DNA extrac-
tion in urine samples than that with both QIAsymphony and
easyMAG extractors (P  0.02 and 0.001, respectively,
Dunn’s multiple-comparison test) and for DNA extraction in
plasma samples compared to QIAsymphony (P 0.03, Dunn’s
multiple-comparison test). The QIAsymphony seemed to show
a higher performance than the easyMAG extractor for WB sam-
ple DNA extraction; however, this difference was at the limit of
statistical significance (P 0.06, Dunn’s multiple-comparison
test) (see Fig. S2 in the supplemental material).
To investigate whether polymorphisms in amplification target
genes might lead to inaccurate BKVL measurement, the StAg,
LTAg, and VP1 gene sequences from samples harboring a single
genotype were aligned with the primers and probes of the in-
house assays. One mismatch was detected in the probe-annealing
site of the assay targeting LTAg (positions 4392 to 4567) (26) for
Comparison of BK Virus DNA Load Assays
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samples BKV14-01/03, BKV14-01/02, BKV14-01/04, and BKV14-
01/08, with no noticeable effect observed on BKVL measurement.
In contrast, the assay targeting VP1 (positions 2227 to 2409) un-
derestimated BKVL values by 1.98 and 0.79 log10 for BKV14-01/03
(genotype IV) and BKV14-04 (genotype II) samples, respectively.
Alignment of the VP1 primers and probe with VP1 sequence
within the BKV14-01/03 sample revealed 5 mismatches, including
3 (G-T, T-T, and T-T) in the center of the forward primer, 1 (T-C)
in the center of the reverse primer, and 1 mismatch (C-T) in the
probe. Four mismatches were detected within the BKV14-04
sample, including 2 in the center of the forward primer, 1 at the
3= end of reverse primer, and 1 in the probe. In the assay tar-
geting StAg (positions 4811 to 4895) (27), a sequence analysis
of the BKV14-04 sample (genotype II) revealed 1 (G-T) and 2
(C-A and C-A) mismatches at the 3= ends of the forward and
reverse primers, respectively, and an additional mutation
(A-T) at the 5= end of the probe. These mismatches are likely to
significantly hinder annealing of the primers and amplification
of the target DNA, and they led to BKVL underestimation by
2.61 log10.
Interestingly, 1 laboratory provided results close to the ex-
pected values for all but 1 sample of the 2014 panel. The BKV load
for BKV14-04 (genotype II) was indeed overestimated by 1.55
log10. This participant used an assay adapted from Hoffman et al.
(17) that was composed of a mixture of primers and probes tar-
geting VP1 (V3A) (positions 2458 to 2525) and StAg (T3A) (po-
sitions 4673 to 4770) simultaneously, in which the StAg primers
and probe were slightly modified to improve amplification of BKV
genotype II/III. As a reference material, this in-house assay used
the ABI control corresponding to the BKV MM strain (GenBank
accession no. V01109). Sequence analysis found no mutation in
the VP1 target gene, while 2 mutations (C4724G and A4726G)
FIG 2 Histograms of reported quantitative values for the positive samples from both panels. BK viral loads are represented in 0.5-log10 copies/ml intervals. Each
rectangle refers to the result of one data set. Each color represents a different technique. The results obtained using commercial techniques are shown in blue and
green, whereas results from in-house methods are colored in orange, red, and purple. The expected value is determined for each sample by calculating the
geometric mean of all reported data set values. Results were obtained for urine (A), whole-blood (B), and plasma (C) specimens.
Solis et al.
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were detected in the center of the probe of the StAg target gene for
genotype I and IV samples. Sequence analysis of the ABI control
found a deletion of 271 bp, including the StAg target gene. Hence,
the VP1 primers and probe perfectly match genotype I samples,
genotype IV samples, and the ABI control, while mismatches in
these samples and the deletion in the ABI control hinder StAg
primers and probe annealing. In contrast, both VP1 and StAg
target genes match the genotype II sample, leading to an overesti-
mation of the BKVL. It should be noted that an erroneous infor-
mation is reported for the ABI control sequence in the supplier’s
FIG 2 continued
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instructions online (tebu-bio, Le Perray-en-Yvelines, France). In-
deed, the BKV MM plasmid is linearized in the StAg gene and not
the VP1 gene.
Infection with multiple BKV genotypes was previously de-
scribed for KTR (31, 32). To further investigate whether this might
impact BKVL quantification, variability between samples harbor-
ing a single genotype and those harboring multiple genotypes was
analyzed by comparing their respective SD (Table 1). No signifi-
cant difference was observed between the 2 groups (P  0.11,
Mann-Whitney test).
As several standard materials were used, there were not suffi-
cient numbers in each group to allow any statistical comparison
for all the data sets. In particular, each commercial kit used by the
study participants contains its own standard material, the compo-
sition of which is proprietary. Nevertheless, we were able in our
laboratory to test both panels by 4 out of the 5 commercial assays
used in this study. For this intralaboratory comparison of com-
mercial kits, assays were strictly conducted according to the man-
ufacturers’ recommendations. In particular, the calibration of
each assay was performed using the standard material included in
the kit. DNA was purified using a single extraction platform. The
standard materials included in the commercial kits did not require
DNA extraction. The percentage of results within the acceptable
range increased from 75% when the assays were performed in
different laboratories to 100% when they were tested by the same
laboratory (see Fig. S3 in the supplemental material), suggesting
that pre-qPCR steps significantly contribute to interlaboratory
variability, more so than standard materials.
FIG 3 Comparison of reported results using in-house and commercial assays. The log10 variation in the reported results relative to the expected value (EV) was
calculated for each positive sample of the panel. The results for commercial and in-house assays are depicted by open diamonds and filled circles, respectively. The
dashed lines indicate a difference of0.5 log10 relative to the EV. The tables specify the percentages of results in the interval EV 0.5 log10 for commercial and
in-house assays. Results were obtained for urine (A), whole-blood (B), and plasma (C) specimens.
Solis et al.
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Analysis of the BKVL SD did not show any significant differ-
ence between the 3 matrices (P 0.08, Kruskal-Wallis test). More
specifically, no significant difference was observed between the 2
blood matrices, plasma and WB (P  0.11, Mann-Whitney test)
(Table 1 and Fig. 4). Last, it has been suggested that levels of viral
DNA, as measured by qPCR, may be dependent on the amplicon
size (19, 33). However, there were no sufficient data in each group
to allow any statistical comparison.
DISCUSSION
BKVL quantification needs to be reproducible and comparable
across time and techniques to ensure appropriate patient care. In
this work, we demonstrate important interlaboratory variability
for the monitoring of BKVL. We believe that this variability limits
interinstitutional comparison and may lead to inadequate BKV
infection monitoring and BKVN diagnosis and management.
The leading event of BKVN seems to be viral replication start-
ing in tubular epithelial cells, followed by urothelial amplification
and cross-feeding back to the tubular compartment (34). The
urine loads of BKV measured in renal allograft recipients result
more from urothelial replication (95%) than from tubular epi-
thelial replication (34). When viral replication can be controlled
by BKV-specific cytotoxic T cells, intragraft inflammation re-
mains limited, and no progression to BKVN ensues (35). BKVL
measured in the blood illustrates persistent viral replication due to
inefficient BKV-specific immunity and persistent inflammation,
which lead to continued tubular epithelial damage. Thus, BKVL
monitoring plays a substantial role in the early detection of BKV
replication in immunocompromised patients and in improve-
ment of the outcome of BKVN.
In this study, we elected to use urine and blood samples with
different BKV genotypes (mono- and multiple infections) for in-
terlaboratory BKVL comparison to mimic the clinical practice.
The qualitative results were overall satisfactory. The only sam-
ple with a false-negative result by a laboratory using an in-house
assay was a WB specimen with a low expected BKVL. Point mu-
tations were detected in the primers and probe, suggesting their
impact on BKV detection. Three laboratories reported false-pos-
itive results for 3 different blood samples. These laboratories used
different commercial qPCR kits and DNA extraction techniques.
However, they performed DNA extraction of both urine and
blood samples on the same platform. A major concern when ex-
tracting nucleic acids for use in amplification reactions is the risk
of cross-contamination, especially when extracting BKV-strongly
positive urine samples interspersed with BKV-negative samples.
The urine samples within our panels harbor high BKVL, suggest-
ing that intersample contamination occurred in the 3 laboratories.
Quantitative results showed important variability, although
68% of the reported results fell within the acceptable range. Com-
pared to other opportunistic viruses in transplant recipients, such
as CMV and EBV (18, 19, 22), it is actually encouraging that two-
thirds of the reported results in our study fell within the acceptable
range. This may be explained by the high number of commercial
assays used in our study that had received approval in Europe. As
the development of BKV assays is more recent, we believe it has
benefited from important progress made in qPCR techniques in
the last decade. This is illustrated by the significant difference in
performance when commercial and in-house assays were com-
pared (76% versus 44%, P 0.0001).
The differences between the highest and the lowest reported
BKVL averaged 2.61 log10 and reached 5.55 log10. BKV genetic
polymorphisms have been described as the most significant
source of error between qPCR assays (17, 22, 30). The composi-
tion of our panels, including different BKV genotypes and the
multiplicity of evaluated qPCR assays, provided a unique oppor-
tunity to define for the first time the effects of mutation frequency
and position on BKVL measurement. All positive samples were
sequenced, and sequences were aligned with the primers and
probes of the in-house assays. Mismatches were found at the
primer and/or the probe annealing-sites in VP1 (positions 2227 to
2409), and LTAg (26), and StAg (27), while the amplification tar-
get region VP1 (positions 2458 to 2532) (17) was highly conserved
in the GenBank database and in our KTR cohort (data not shown).
The number of mismatches in the primers and/or probes and their
distance from the 3= end of the primer highly impacted BKVL
measurement. For example, 3 mismatches at the 3= end position of
primers led to BKVL underestimation by 2.61 log10, while 3 other
primer mismatches (1 at the 3= end position and 2 located8 bp
from it) led to BKVL underestimation by 0.79 log10. Further-
more, no specific effect was observed with a single mismatch in
the probe or at the 5=-end position of the primers. A compar-
FIG 4 Distribution of the standard deviations according to the expected BKVL. Standard deviations (SD) are represented by black diamonds for urine samples,
gray triangles for plasma samples, and open circles for the whole-blood samples. The SD ranged from 0.33 to 1.07 log10 copies/ml. No difference in variability was
found across the analytical measuring range. The variability of BKVL in the 3 matrices (urine, WB, and plasma) was not statistically different (P  0.08,
Kruskal-Wallis test). The greatest SD (1 log10) was observed for the BKV genotype II sample.
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ison of the BKV sequences of our panel samples with sequences
from the GenBank database and from our local KTR cohort
revealed that these mutations were genotype specific (66 to
100% for genotype II/III and 100% for genotype IV) (data not
shown). BKV genotype III is not represented in our study, since
none of our patients were infected by BKV genotype III (geno-
type III represents 1% of the BKV isolates in Europe). How-
ever, several studies using phylogenetic and single-polymor-
phism analyses of BKV DNA sequences suggest that BKV
genotypes II and III may belong to the same genotype, since
only a few nucleotides differ between them (36–38). Further-
more, a comparison of the BKV sequences of our panel samples
with sequences from the GenBank database revealed that all the
mutations observed in the genotype II samples were specific
not only to this genotype but also to genotype III strains.
Our BKV sequence analyses suggest that the primers and
probes of most in-house assays were designed solely against geno-
type I, while commercial assays allow the amplification of the ma-
jor BKV genotypes, as claimed by the manufacturers. Due to the
proprietary nature of commercial reagents, we could not analyze
the presence of mutations in the amplification target genes of
commercial assays that may impact qPCR amplification. How-
ever, the high performance of commercial assays does not support
the presence of such mutations. Altogether, our data suggest that
commercial external quality controls for BKVL assessment should
include all the major BKV genotypes to allow correct evaluation of
BKV assays.
BKVL quantification may also be influenced by polymor-
phisms in standard materials. Henriksen et al. (39) recently
reported the presence of point mutations in the plasmid pBKV
Dunlop (ATCC 45025) in comparison to the published se-
quence and indicated that these mutations may alter BKVL
quantification, since pBKV is used as a positive control in many
qPCR assays (39). In our study, we demonstrate the impact of
the sequence variation of a BKV control used as a standard
material for quantification. Due to a deletion in this plasmid,
BKVL was overestimated up to 1.55 log10. Our data strongly
suggest that the sequence of BKV commercial standards should
be provided to users to verify the absence of mismatches with
the primers and probes of their BKV assays. Alternatively, vi-
rologists should sequence the commercialized control they in-
tend to use as standard material.
The standard material used to establish the calibration curves
in qPCR is an important source of interlaboratory disagreements
(23). We recently demonstrated that recalibration with a common
standard material significantly reduced the bias between a com-
mercial assay and an in-house assay (23). Here, by retesting BKV
panels by 4 commercial assays in a single laboratory, we show that
commercial standard materials are equivalent, suggesting that this
factor only poorly contributes to interlaboratory variability, at
least for commercial assays. Moreover, the development of the
WHO international standard will probably decrease the impact of
this interlaboratory variability factor, provided the publication of
the nucleotide sequence will occur to allow each laboratory and
commercial assay supplier to verify the absence of mismatches
with the primers and probes of their BKV qPCR assays.
The use of plasma or WB for viral load monitoring is still de-
bated, although WB remains the preferred clinical sample type for
detecting CMV and EBV in numerous diagnostic laboratories (40,
41). We recently demonstrated that the BKVL measured in plasma
and WB are highly correlated (23). In the present multisite study,
we further show that the variability within each matrix is not sig-
nificantly different. We thus provide evidence of equivalence be-
tween plasma and WB as suitable matrices for BKV detection and
quantification in peripheral blood. In the case of CMV and EBV,
viral loads measured in WB reflect both free DNA and leukocyte-
associated DNA (18, 19). In contrast, BKV viremia mostly reflects
free DNA, although BKV DNA has been detected in peripheral
blood mononuclear cells (42).
Every year, more than 3,000 patients undergo kidney trans-
plantation in France, and most of them (90%) are routinely
screened for BKV (more than 45,000 tests/year) in the laboratories
participating in this study. These laboratories use a variety of ex-
traction techniques and qPCR assays, whether published in house
(26, 27) or as commercial assays. We therefore believe that the
results of this study are representative of the current status of BKV
monitoring in Europe and the United States.
In summary, the results of this comparative study demonstrate
that significant interlaboratory variability in BKVL quantification
exists and may significantly impact patient care. Genotype II- and
IV-specific polymorphisms and a range of DNA purification
methods arose as major sources of interlaboratory disagreement.
The optimization of primer and probe design and the standard-
ization of DNA extraction methods may substantially decrease
interlaboratory variability and allow interinstitutional studies to
define a universal cutoff for presumptive BKVN and, ultimately,
to ensure adequate patient care.
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